Vaxcyte, Inc. announced that it has appointed John Furey, a seasoned industry expert, to its Board of Directors. Mr. Furey is a seasoned biopharmaceutical executive with over 30 years of experience developing and implementing operational strategies and leading commercial and technical teams, including senior leadership roles in the U.S., Europe and Asia. He currently serves as Chief Executive Officer of Imvax.

Prior to Imvax, Mr. Furey was Chief Operating Officer of Spark Therapeutics, where he led the successful U.S. launch of LUXTURNA?, the first FDA-approved gene therapy for a genetic disease, and contributed to the build-out of Spark Therapeutics as a fully integrated company. Mr. Furey also served as Senior Vice President and Head of Global Operations at Baxalta, where he led the team that successfully established the company through a spin-out from Baxter, directed manufacturing and supply chain, and delivered significant growth of the Baxter Vaccine inline business. Prior to Baxter, he spent several years at Pfizer in roles of increasing scope and responsibility, including as the General Manager of the vaccine business unit in China and a leadership role overseeing Pfizer Vaccines?

global pricing and reimbursement. Earlier in his career, Mr. Furey held both commercial and operations positions at Wyeth Pharmaceuticals (prior to Pfizer?s acquisition of Wyeth), including serving as Project Director of the Grange Castle Biopharmaceutical Campus where Prevnar is manufactured. Mr. Furey earned an executive Master of Business Administration from Saint Joseph?s University, a Bachelor of Science degree from Trinity College, Dublin, and a Diploma in Environmental Health from the Technological University, Dublin.

Mr. Furey also serves on the Board of Directors of Adaptimmune and Sensorion.